| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | 6.1% | $15,091,828 | 13,346,151 | Kenneth Griffin | 09 Jul 2025 | |||
| Belldegrun Arie | 5.6% | -1.7% | $15,708,747 | +$77,438 | 12,668,344 | +0.5% | Arie Belldegrun, M.D. | 30 Sep 2025 |
| BlackRock, Inc. | 5.3% | $17,633,122 | 11,450,079 | BlackRock, Inc. | 31 Mar 2025 | |||
| Chang David D | 4.9% | -2% | $13,931,298 | +$121,756 | 11,234,918 | +0.88% | David D. Chang, M.D., Ph.D. | 30 Sep 2025 |
| Lynx1 Capital Management LP | 5.2% | $16,747,073 | 10,874,723 | Lynx1 Capital Management LP | 31 Dec 2024 | |||
| FMR LLC | 4.9% | -58% | $15,747,811 | -$20,861,062 | 10,225,851 | -57% | FMR LLC | 28 Feb 2025 |
As of 30 Sep 2025, 167 institutional investors reported holding 162,111,006 shares of Allogene Therapeutics, Inc. - Common Stock (ALLO). This represents 72% of the company’s total 226,220,429 outstanding shares.
The largest institutional shareholders of Allogene Therapeutics, Inc. - Common Stock (ALLO) together control 62% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Pfizer Inc | 9.7% | 22,032,040 | 0% | 6.2% | $27,319,730 |
| TPG GP A, LLC | 8.3% | 18,716,306 | 0% | 1.3% | $23,208,219 |
| BlackRock, Inc. | 7.7% | 17,514,674 | -2.1% | 0% | $21,718,195 |
| CITADEL ADVISORS LLC | 6.2% | 13,971,557 | +36% | 0.01% | $17,324,731 |
| VANGUARD GROUP INC | 4% | 9,020,770 | +9.2% | 0% | $11,185,755 |
| PRIMECAP MANAGEMENT CO/CA/ | 3.1% | 7,079,308 | +24% | 0.01% | $8,778,342 |
| Woodline Partners LP | 1.9% | 4,360,608 | 0% | 0.03% | $5,407,154 |
| Frazier Life Sciences Management, L.P. | 1.7% | 3,868,750 | 0% | 0.14% | $4,797,250 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 3,833,885 | +1% | 0% | $4,754,796 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.6% | 3,677,474 | -8.8% | 0% | $4,561,000 |
| UBS Group AG | 1.6% | 3,571,157 | +75% | 0% | $4,428,235 |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 3,390,026 | +126% | 0% | $4,203,632 |
| TWO SIGMA INVESTMENTS, LP | 1.5% | 3,383,644 | +110% | 0.01% | $4,195,719 |
| Patient Square Capital LP | 1.3% | 2,981,396 | +13% | 0.99% | $3,696,931 |
| Wildcat Capital Management, LLC | 1.3% | 2,920,787 | 0% | 2.5% | $3,621,776 |
| RENAISSANCE TECHNOLOGIES LLC | 1.3% | 2,893,812 | +73% | 0% | $3,588,327 |
| TWO SIGMA ADVISERS, LP | 1.2% | 2,781,600 | +57% | 0.01% | $3,449,184 |
| STATE STREET CORP | 1.2% | 2,755,378 | +1.2% | 0% | $3,416,669 |
| DIMENSIONAL FUND ADVISORS LP | 0.92% | 2,090,753 | -24% | 0% | $2,592,869 |
| AQR CAPITAL MANAGEMENT LLC | 0.82% | 1,853,554 | +2199% | 0% | $2,298,407 |
| Vida Ventures Advisors, LLC | 0.79% | 1,798,163 | 0% | 7.6% | $2,229,722 |
| Aberdeen Group plc | 0.7% | 1,582,265 | +82% | 0% | $1,962,009 |
| DAFNA Capital Management LLC | 0.61% | 1,380,118 | 0% | 0.42% | $1,711,346 |
| MORGAN STANLEY | 0.57% | 1,299,166 | +113% | 0% | $1,610,966 |
| NORTHERN TRUST CORP | 0.57% | 1,279,628 | +0.42% | 0% | $1,586,739 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 2,194,369 | $3,008,675 | +$724,546 | $1.37 | 9 |
| 2025 Q3 | 162,111,006 | $201,030,848 | -$24,340,170 | $1.24 | 167 |
| 2025 Q2 | 183,617,614 | $207,883,293 | -$15,409,926 | $1.13 | 153 |
| 2025 Q1 | 196,986,783 | $288,577,139 | +$11,150,657 | $1.46 | 167 |
| 2024 Q4 | 188,657,885 | $401,850,158 | -$12,907,825 | $2.13 | 170 |
| 2024 Q3 | 164,371,652 | $460,365,265 | -$1,917,859 | $2.80 | 152 |
| 2024 Q2 | 165,184,059 | $384,891,280 | +$75,138,227 | $2.33 | 169 |
| 2024 Q1 | 131,205,694 | $586,006,096 | +$44,997,765 | $4.47 | 158 |
| 2023 Q4 | 122,248,338 | $392,448,357 | -$24,859,731 | $3.21 | 167 |
| 2023 Q3 | 130,384,371 | $413,319,837 | -$17,479,237 | $3.17 | 152 |
| 2023 Q2 | 133,404,417 | $662,853,148 | +$77,627,682 | $4.97 | 168 |
| 2023 Q1 | 117,863,372 | $582,311,658 | +$28,545,426 | $4.94 | 174 |
| 2022 Q4 | 111,615,016 | $701,714,273 | +$16,748,007 | $6.29 | 166 |
| 2022 Q3 | 106,389,695 | $1,148,387,442 | +$56,535,530 | $10.80 | 182 |
| 2022 Q2 | 100,792,050 | $1,148,985,365 | +$110,979,207 | $11.40 | 155 |
| 2022 Q1 | 91,688,120 | $835,872,818 | +$16,130,116 | $9.11 | 173 |
| 2021 Q4 | 85,813,394 | $1,280,601,899 | -$105,097,078 | $14.92 | 168 |
| 2021 Q3 | 86,172,174 | $2,214,699,254 | +$36,168,155 | $25.70 | 165 |
| 2021 Q2 | 86,340,537 | $2,251,293,398 | -$84,504,708 | $26.08 | 175 |
| 2021 Q1 | 86,575,661 | $3,055,834,294 | -$11,800,278 | $35.30 | 167 |
| 2020 Q4 | 87,569,716 | $2,210,441,766 | +$86,472,875 | $25.24 | 160 |
| 2020 Q3 | 83,175,052 | $3,136,521,357 | -$164,131,449 | $37.71 | 158 |
| 2020 Q2 | 86,937,058 | $3,722,235,026 | +$671,195,013 | $42.82 | 170 |
| 2020 Q1 | 73,747,853 | $1,390,700,983 | +$46,546,025 | $19.44 | 115 |
| 2019 Q4 | 71,621,156 | $1,860,741,066 | +$73,711,322 | $25.98 | 114 |
| 2019 Q3 | 68,693,966 | $1,760,955,637 | +$43,711,782 | $27.26 | 94 |
| 2019 Q2 | 68,882,259 | $1,691,632,297 | +$152,108,493 | $26.85 | 94 |
| 2019 Q1 | 65,390,655 | $1,661,573,471 | +$80,500,361 | $28.91 | 85 |
| 2018 Q4 | 54,998,315 | $1,469,849,010 | +$1,469,849,001 | $26.93 | 78 |
| 2016 Q2 | 0 | $0 | -$115,000 | $1.37 | 0 |
| 2016 Q1 | 4,033 | $115,000 | $28.51 | 1 |